Business Wire

ADVA

22.7.2021 07:02:12 CEST | Business Wire | Press release

Share
ADVA posts record results for Q2 2021

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported record financial results for Q2 2021 ended on June 30, 2021. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005791/en/

Q2 2021 financial summary1

(in thousands of EUR)

Q2

Q2

Change

Q1

Change

 

 

2021

2020

 

2021

 

 

 

 

Revenues

149,354

145,024

3.0%

144,473

3.4%

 

Pro forma gross profit

57,274

50,204

14.1%

55,345

3.5%

 

in % of revenues

38.3%

34.6%

3.7pp

38.3%

0.0pp

 

Pro forma operating income

14,415

10,107

42.6%

12,860

12.1%

 

in % of revenues

9.7%

7.0%

2.7pp

8.9%

0.8pp

 

Operating income (loss)

13,036

8,658

50.6%

11,573

12.6%

 

Net income

12,001

7,629

57.3%

11,228

6.9%

 

 

 

(in thousands of EUR)

Jun. 30

2021

Jun. 30

2020

Change

Mar. 31

2021

Change

 

Cash and cash equivalents

85,023

67,586

25.8%

79,060

7.5%

 

Net cash (+) / Net debt (-)

3,876

-44,928

n.a.

-10,626

n.a.

 

Net working capital

132,767

127,917

3.8%

125,785

5.6%

 

1 Potential difference due to rounding

Q2 2021 IFRS financial results

Revenues in Q2 2021 reached EUR 149.4 million, up by 3.4% from EUR 144.5 million in Q1 2021, also up by 3.0% compared to EUR 145.0 million in Q2 2020. As in the first quarter of the fiscal year, this success was particularly due to high order volume from communication service providers as well as private enterprises and governments.

Pro forma gross profit in Q2 2021 increased by 3.5%, reaching EUR 57.3 million (38.3% of revenues) compared to EUR 55.3 million (38.3% of revenues) in Q1 2021 and increased considerably by 14.1% compared to EUR 50.2 million (34.6% of revenues) reported in Q2 2020. Software and service revenue contribution was strong, and the customer and product mix also supported the gross margin growth.

Pro forma operating income for Q2 2021 was EUR 14.4 million (9.7% of revenues) and increased by 12.1% compared to EUR 12.9 million (8.9% of revenues) reported in Q1 2021. Compared to Q2 2020, pro forma operating income improved significantly by 42.6% from EUR 10.1 million (7.0% of revenues).

Operating income for Q2 2021 of EUR 13.0 million increased by 12.6% from EUR 11.6 million reported for Q1 2021 and significantly increased by 50.6% from EUR 8.7 million in Q2 2020.

Net income reached EUR 12.0 million in Q2 2021, up by 6.9% from EUR 11.2 million in Q1 2021, and significantly up by 57.3% from EUR 7.6 million in Q2 2020.

The company’s cash and cash equivalents totaled EUR 85.0 million, representing an increase of EUR 5.9 million compared to EUR 79.1 million at the end of Q1 2021. Year-over-year cash and cash equivalents substantially increased by EUR 17.4 million from EUR 67.6 million at the end of Q2 2020.

Net cash at the end of Q2 2021 stood at EUR 3.9 million when compared to net debt positions of EUR 10.6 million at the end of Q1 2021 or EUR 44.9 million at the end of Q2 2020, respectively. Thus, Q2 2021 was the first quarter showing a net cash position since the introduction of the accounting standard IFRS 16.

Net working capital at quarter-end was EUR 132.8 million and increased by EUR 7.0 million compared to EUR 125.8 million at the end of Q1 2021.

Management commentary

“We continue to grow our business, showing profits and building our financial resources,” said Brian Protiva, CEO, ADVA. “The macro-environment for our industry continues to be good. The digitization efforts in many global regions are in full swing, and the expansion of communication infrastructure is moving at speed. Security is on the top of our customers’ digital agenda, and we are sharpening our profile as the supplier of choice for trusted network infrastructure. With a record-level order backlog, we will continue to use all of our strengths to produce results that allow us to be a leader in a consolidating market.”

“The second quarter of 2021 marked another record quarter in terms of profitability. While continuing to execute our business transformation strategy, we were able to absorb higher purchase prices of components due to the semiconductor crisis and reached a pro forma EBIT of 9.7%,” commented Uli Dopfer, CFO, ADVA. “Also, cash generation was once again very positive. Despite debt repayments of EUR 7.5 million, we were able to increase cash by EUR 6 million and now report a net cash position of EUR 3.9 million also when applying IFRS 16. With that strong first six months in the bank, I am encouraged that we will manage the current supply bottlenecks and reach for the full year a pro forma EBIT between 7% and 10% of revenues.”

Financial outlook 2021

For the fiscal year 2021, ADVA expects revenues to be in the range of EUR 580 million and EUR 610 million and a pro forma operating income of between 7.0% and 10.0% of revenues.

The company will publish its financial results for Q3 2021 on October 21, 2021.

Conference call details

ADVA will hold a conference call for analysts and investors today, July 22, 2021, to discuss the Q2 2021 results. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website:

https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete half-year report 2021 (January – June) is available as a PDF:

https://www.adva.com/en/about-us/investors/financial-results/financial-statements

A replay of the call will be available here:

https://www.adva.com/en/about-us/investors/financial-results/conference-calls

Forward-looking statements

The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information

ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye